<DOC>
	<DOCNO>NCT01939054</DOCNO>
	<brief_summary>Nimotuzumab IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) , inhibit tyrosine kinase activation . This randomize , control , open-Label , multicenter , phase Ⅱ clinical trial nimotuzumab plus Docetaxel Capecitabine（TX）versus Docetaxel Capecitabine（TX）as first-line treatment patient recurrent/metastatic triple negative breast cancer .</brief_summary>
	<brief_title>Nimotuzumab Plus Docetaxel Capecitabine Versus Docetaxel Capecitabine Treatment Breast Cancer Patients</brief_title>
	<detailed_description>The control group receive docetaxel + capecitabine regimen ; Experimental group receive Nimotuzumab combine docetaxel + capecitabine regimen.The main purpose evaluate Nimotuzumab Plus Docetaxel Capecitabine（TX）as First-Line Treatment Patients With Recurrent/Metastatic triple negative breast cancer would improve objective response rate ( ORR ) compare Docetaxel Capecitabine（TX） .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Histological immunohistochemistry ( IHC ) confirm recurrent metastatic triplenegative breast cancer . 2 . Previous chemotherapy include anthracycline taxane ; No prior chemotherapy metastasis . 3 . Females age 18 70 year old 4 . ECOG performance status 0 1 . 5 . At least one measurable disease accord response evaluation criterion solid tumor ( RECIST ) magnetic resonance imaging , compute tomography ; The target lesion Unresectable ; The target lesion receive radiotherapy relapse within radiation field ; 6 . Life expectancy ≥ 12 weeks.； 7 . WBC count ≥ 4 × 109 / L , neutrophils ≥ 1.5 × 109 / L , platelet count ≥ 100 × 109 / L , hemoglobin ≥ 6.21mmol / L ( 10 g / dL ) ; 8 . Total bilirubin ( TBL ) ≤ 1.5 x ULN ( upper limit normal reference value ) ; AST ALT ≤ 2.5 x ULN ≤ 5 ULN ( Liver metastasis ) ; Serum creatinine ≤ 1.5 x ULN . 9 . Before enrollment , patient fully recover previous treatmentrelated toxicity ; 10 . Subjects fertility must accept effective contraceptive measure ; 11 . Signed informed consent 1 . Previously treatment regimen include anti EGFR monoclonal antibody ; 2 . Receiving anticancer medicine treatment study 3 . Participate clinical trial within 4 week group ; 4 . Accepted taxane treatment 1 year ; 5 . Presence neurological symptom due brain metastasis , patient receive steroidal antiedema drug therapy ; 6 . Patients history clinically significant symptomatic angina , arrhythmia congestive heart failure without control ; 7 . Diagnosed severe interstitial pneumonitis pulmonary fibrosis chest CT ; 8 . Pleural effusion , ascites require drain ; 9 . Adverse drug addiction drug abuse , longterm alcoholic , well AIDS patient ; patient severe uncontrolled complication , infection require systemic therapy , fever ( ≥ 38 ℃ ) , diabetes hypertension control medicine , complication may interfere drug therapy ; 10 . Patients history drug allergy ( ≥ CTCAE 2 level ) shock allergic symptom , especially allergic reaction similar drug past , severe allergy reaction drug contain polysorbate eighty ( Tween 80 ) ; 11 . Uncontrolled seizure loss insight due mental disorder ; 12 . Pregnant lactate women； 13 . Researchers think improper trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>